This bill mandates the Secretary of Health and Human Services to launch a 2-year nationwide demonstration program within one year of enactment. The program's core purpose is to test the mandatory inclusion of specific wound care treatments for epidermolysis bullosa as medical assistance under the Medicaid program. These covered items and services include over-the-counter antihistamines, acetaminophen, NSAIDs, antiseptics, zinc oxide, antibiotic ointments, and essential wound care supplies like dressings, gauze, and bandage retainers. Following the program's conclusion, the Secretary must submit a report to Congress. This report will evaluate the program's effect on Medicaid expenditures, analyze health outcomes for individuals with epidermolysis bullosa, and provide recommendations to prevent hospitalizations related to the condition.